Although not fully understood, SGLT-2 inhibitors may impact oxalate metabolism by increasing hypercalciuria, which can indirectly elevate urinary oxalate excretion and enhance the risk of calcium oxalate stone formation. Here, SLC5A2 is linked to Hypercalciuria.